ChronoScale expands AI contracts: what it means for ChronoScale stock

Published on 10/14/2026 at 05:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue fell 15.00 percent to USD 71.60 million. For ChronoScale stock, the next shareholder meeting is November 6, 2026.

Contract scale and capital needs

On October 1, 2026, ChronoScale said new agreements support USD 1.00 billion in annualized run-rate revenue.
Fiscal 2026 revenue fell 15.00 percent to USD 71.60 million.
ChronoScale stock was last at USD 16.31 on Nasdaq on October 13, 2026 at 4:00 p.m. ET.
The annual meeting is scheduled for November 6, 2026.

CHRN, US2826444000, Illustration mit AI erstellt.

ChronoScale (US2826444000) said on October 1, 2026, that an expanded customer agreement and a new AI infrastructure contract support USD 1.00 billion in annualized run-rate revenue by the calendar third quarter of 2027. The company also completed the sale of its Ekso Bionics business unit, according to ChronoScale in its October 1, 2026 release.

AI contracts reach USD 1.00 billion

The agreements extend ChronoScale's contracted deployment pipeline and are tied to existing contracts and the current deployment schedule. The company defines annualized run-rate revenue as a non-GAAP operating metric calculated by multiplying contract revenue recognized in a quarter by four, rather than as a forecast for a specific reporting period.

The sale changes the business mix. ChronoScale said the divestiture lets it concentrate operations, management resources and capital allocation on accelerated computing and AI infrastructure.

Why the USD 1.00 billion matters

Yahoo Finance reported on October 6, 2026, that fiscal 2026 revenue fell 15.00 percent to USD 71.60 million, while the operating loss narrowed 32.00 percent to USD 37.50 million. The USD 1.00 billion run-rate ambition therefore represents a materially larger annualized scale than the latest completed fiscal year, but the metric depends on deployment execution and financing.

ChronoScale's filing describes customer concentration and access to capital as risks. Its filing also says the company may offer up to USD 500.00 million of securities under a shelf registration, a financing capacity rather than a completed offering, according to StockTitan on October 6, 2026.

Three milestones shape the transition

On May 5, 2026, ChronoScale completed the combination that created the current public company. On August 6, 2026, it entered a two-year Microsoft partnership supporting a planned 50-megawatt AI compute deployment, and on September 30, 2026, it completed the Legacy Ekso divestiture, according to StockTitan.

Dates investors can verify

The next scheduled shareholder meeting is November 6, 2026, at 12:00 p.m. EDT, according to the company's investor-relations page. The Microsoft deployment is expected in the first calendar quarter of 2027, while the contracted run-rate target is set for the calendar third quarter of 2027.

The latest Nasdaq quote

ChronoScale was last at USD 16.31 on the Nasdaq on October 13, 2026, at 4:00 p.m. ET. The quote followed a USD 17.88 previous session close in the structured market data, while the company remains focused on converting contracted demand into operating capacity.